Aspira Women’s Health (NASDAQ:AWH) Lifted to Hold at StockNews.com

Aspira Women’s Health (NASDAQ:AWH) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.

Separately, Cantor Fitzgerald cut their price target on Aspira Women’s Health from $4.00 to $3.30 and set a “neutral” rating for the company in a research note on Monday.

Aspira Women’s Health Price Performance

Shares of NASDAQ AWH opened at $2.74 on Wednesday. Aspira Women’s Health has a 1-year low of $2.31 and a 1-year high of $6.75. The business’s fifty day moving average price is $4.17 and its two-hundred day moving average price is $4.23. The firm has a market capitalization of $28.28 million, a PE ratio of -0.23 and a beta of 1.61.

Institutional Investors Weigh In On Aspira Women’s Health

A number of institutional investors and hedge funds have recently modified their holdings of AWH. JPMorgan Chase & Co. grew its position in shares of Aspira Women’s Health by 126.3% during the 1st quarter. JPMorgan Chase & Co. now owns 64,839 shares of the company’s stock worth $67,000 after purchasing an additional 36,189 shares in the last quarter. Private Advisor Group LLC lifted its holdings in shares of Aspira Women’s Health by 361.8% during the 1st quarter. Private Advisor Group LLC now owns 69,697 shares of the company’s stock worth $73,000 after acquiring an additional 54,603 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Aspira Women’s Health by 5.7% during the 1st quarter. Vanguard Group Inc. now owns 3,067,896 shares of the company’s stock worth $3,191,000 after acquiring an additional 164,635 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Aspira Women’s Health by 18.5% during the 1st quarter. Renaissance Technologies LLC now owns 1,132,801 shares of the company’s stock worth $1,178,000 after acquiring an additional 177,075 shares during the period. Finally, Atria Wealth Solutions Inc. bought a new stake in shares of Aspira Women’s Health during the 1st quarter worth approximately $49,000. 12.19% of the stock is owned by institutional investors.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering.